中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell

文献类型：期刊论文

作者Zhang, Hanyan1; Sun, Dandan2; Wang, Guanzhen2; Cui, Shichao2; Field, Robert A.3; Li, Jia2; Zang, Yi2
刊名BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
出版日期2019-04-02
卷号511期号:2页码:387-393
ISSN号0006-291X
关键词DPP4 Alogliptin Liver fibrosis Hepatic stellate cell
DOI10.1016/j.bbrc.2019.02.065
通讯作者Li, Jia(jli@simm.ac.cn) ; Zang, Yi(yzang@simm.ac.cn)
英文摘要Liver fibrosis occurs in most types of chronic liver diseases. The understanding of the pathogenesis of liver fibrosis has grown considerably, but the effective treatments are still lacking. Alogliptin, a classical Dipeptidyl peptidase-4 (DPP4) inhibitor with great effects on type 2 diabetes, has shown the potential to protect liver, but its effects on the progression of liver fibrosis have not been clarified. Herein, we explored the anti-fibrosis effects of alogliptin. In vitro, we demonstrated that alogliptin suppressed the activation of LX-2 upon transforming growth factor-beta (TGF-beta) challenge. In vivo, chronic treatment with alogliptin alleviated hepatic steatosis and protected from the liver injury in ob/ob mice, which delayed the progression of liver fibrosis. Furthermore, alogliptin significantly relieved the hepatic fibrosis in CCI4-induced liver fibrosis mouse model. In conclusion, our results demonstrate that negatively modulation of alogliptin on hepatic stellate cell (HSC) activation might contribute to liver fibrosis alleviation. Our research provides the potential possibility of alogliptin on the application for liver fibrosis therapy and suggests that DPP4 may be a novel target for liver fibrosis therapy. (C) 2019 Elsevier Inc. All rights reserved.
WOS关键词DIPEPTIDYL PEPTIDASE-4 INHIBITOR ; PATHOGENESIS ; REGENERATION ; NAFLD ; DPP4
资助项目National Natural Science Foundation of China[31871414] ; National Natural Science Foundation of China[81673489] ; Science and Technology Commission of Shanghai Municipality[16430724100] ; K. C. Wong Education Foundation
WOS研究方向Biochemistry & Molecular Biology ; Biophysics
语种英语
出版者ACADEMIC PRESS INC ELSEVIER SCIENCE
WOS记录号WOS:000461404700029
源URL[http://119.78.100.183/handle/2S10ELR8/290365]  
专题新药研究国家重点实验室
通讯作者Li, Jia; Zang, Yi
作者单位1.Nanchang Univ, Sch Pharm, 461 Bayi Rd, Nanchang 330006, Jiangxi, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Natl Ctr Drug Screening, Shanghai 201203, Peoples R China
3.John Innes Ctr, Dept Biol Chem, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England
推荐引用方式
GB/T 7714		 Zhang, Hanyan,Sun, Dandan,Wang, Guanzhen,et al. Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,2019,511(2):387-393.
APA Zhang, Hanyan.,Sun, Dandan.,Wang, Guanzhen.,Cui, Shichao.,Field, Robert A..,...&Zang, Yi.(2019).Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell.BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,511(2),387-393.
MLA Zhang, Hanyan,et al."Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell".BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 511.2(2019):387-393.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。